Trials & Tribulations What NHS-Galleri taught us—and what it didn’t June 18, 2026Vol.52 No.24By Scott D. Ramsey and Ruth Etzioni
Trials & Tribulations The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies June 18, 2026Vol.52 No.24By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari
News Analysis FDA clears a way for dramatic reduction in animal toxicology studies in cancer June 18, 2026Vol.52 No.24By Claire Marie Porter
Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” June 12, 2026Vol.52 No.23By Jacquelyn Cobb
Capitol Hill House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget June 12, 2026Vol.52 No.23By Paul Goldberg
As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick labThe job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded June 12, 2026Vol.52 No.23By Paul Goldberg
FreeTrials & Tribulations Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy June 12, 2026Vol.52 No.23By Peter F. Garrett
Sponsored Survivorship begins at diagnosis—cancer care system must recognize this June 12, 2026Vol.52 No.23By Saro Armenian
Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival June 05, 2026Vol.52 No.22By Jacquelyn Cobb
Trials & Tribulations The story of daraxonrasib is the ultimate hero’s journeyA narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe June 05, 2026Vol.52 No.22By W. Kimryn Rathmell
